Noteworthy, the blockade of the cannabinoid receptor type-1 (CB1) was shown to attenuate insulin resistance, glucose intolerance, dyslipidemia, diet-induced obesity, inflammation, and cardiometabolic risk factors [214,215,216]. The gene discussed is CNR1; the disease is obesity due to melanocortin 4 receptor deficiency.